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1. Introduction
Meningitis continues to claim many lives, despite the availability of potent antibiotics to 
destroy the deadly pathogens. Acute bacterial meningitis (ABM) is an uncommon but poten-
tially fatal neurologic emergency that requires prompt recognition, diagnostic evaluation, 
and initiation of parenteral antibiotics [1]. Bacterial meningitis is very serious and can be 
deadly. Death can occur in as little as a few hours.
Common causes of bacterial meningitis vary by age group (newborns, babies and children, 
teens and young adults, older adults). And certain people are at increased risk for bacte-
rial meningitis, those including: age, community setting, certain medical conditions, working 
with meningitis-causing pathogens, and travel [1].
It is very important to highlight the clinical overlap between encephalitis and meningo 
encephalitis.
The diagnosis becomes challenging when patients present with nonspecific clinical features. 
Meningitis results from inflammation of the pia-arachnoid meninges as well as cerebrospinal 
fluid [2, 3]. Encephalitis refers to inflammation of the brain parenchyma and is typically char-
acterized by cognitive deficits. Of the pathogens reported to cause encephalitis, the majority 
are viruses.
However, despite extensive testing, the etiology of encephalitis remains unknown in most 
patients. Another major challenge for patients with encephalitis is to determine the relevance 
of an infectious agent identified outside of the CNS; these agents may play a role in the neu-
rologic manifestations of illness but not necessarily by directly invading the CNS. In addi-
tion, it is important to distinguish between infectious encephalitis and post infectious or post 
immunization encephalitis, encephalomyelitis [e.g., acute disseminated encephalomyelitis 
(ADEM)], which may be mediated by an immunologic response to an antecedent antigenic 
stimulus from an infecting microorganism or immunization [4].
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It is important to realize that guidelines cannot always account for individual variation among 
patients. They are not intended to supplant physician judgment with respect to particular 
patients or special clinical situations. The Infectious Diseases Society of America considers adher-
ence to these guidelines to be voluntary, with the ultimate determination regarding their appli-
cation to be made by the physician in the light of each patient’s individual circumstances [4].
The clinical distinction between meningitis and encephalitis is frequently blurred as patients 
often present with signs and symptoms of both conditions. These patients can best be described 
as having meningoencephalitis, the pathologic condition that results when inflammation 
spreads from the CSF and meninges to the adjacent brain parenchyma [1]. Inflammation of 
the central nervous system can be acute, subacute, or chronic in duration and community, 
or nosocomial in origin. Although meningeal inflammation may be due to medications, neo-
plastic or autoimmune processes, or nonbacterial microbes (e.g., viruses, fungi, or parasites), 
bacterial infection remains the most studied cause.
The existing literature on ABM is limited in several ways. First, much of the research on the 
pathophysiology of meningitis has been based on experimental rabbit and rat models. Second, 
much of our current understanding about the clinical features, diagnosis, and prognosis of 
ABM has been extracted from chart reviews. These reviews rarely report methodology and 
are heavily dependent on the availability and accuracy of the medical records. Furthermore, 
because reviewers cannot adequately control for confounding variables, the retrospective data 
cannot be used to establish cause-effect relationships; only potential associations between 
variables can be pointed out. Third, a good number of trials involving bacterial etiology and 
therapy have been conducted in the international setting. In general, the results of these stud-
ies cannot be extrapolated to practice within the United States. The external validity of all 
studies must be assessed before a new treatment strategy can be adopted [1].
It is always very important to distinguish community-acquired bacterial meningitis from 
encephalitis, aseptic meningitis, and intracranial abscess.
Microbiologists play a critical role in gathering data both for clinical and public health deci-
sion making [5]. Thus, high-quality surveillance, including molecular methods and fine typ-
ing, is crucial to accurately detect and assess changes in the epidemiology of bacteria (e.g., 
invasive meningococcal disease) and ensure sufficient understanding of the need for, and 
impact and effectiveness of, vaccination [5].
The priority of the vaccine and how it can be integrated into the national immunization pro-
gram are also important to consider [6]. Considering these factors, the cost effectiveness and 
feasibility of introducing a new vaccine needs to be based on country-specific assessments [7].
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